Amazon's Spring Sale has amazing deals on jeans that we're scooping up for the season — get styles from Levi's, Wrangler and more up to 70% off March Madness 2026: How to watch the South Carolina vs.

The biggest stories of the day delivered to your inbox.

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

Tesla has announced the Powerwall 3P, a new variant of its home battery with a native three-phase inverter built into a single unit. The product, announced for the German market first, eliminates the ...

Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...

A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a ...

Both dosage regimens of amlitelimab were associated with statistically significant improvements in skin clearance and disease severity vs placebo in the US estimand. Topline data were announced from ...

In power distribution systems, three-phase transformer configuration directly impacts system reliability and load management. Understanding the trade-offs between Delta and Wye connections enables ...

(RTTNews) - SELLAS Life Sciences Group Inc. (SLS) reported that survival in its pivotal Phase 3 REGAL trial is extending longer than anticipated, delaying the occurrence of the 80th event required to ...

Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

First patient randomized into HELIOS-3, which along with HELIOS-2 form the basis of AXPAXLI’s registrational program in non-proliferative diabetic retinopathy (NPDR) HELIOS-2 and HELIOS-3 are global, ...